Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl noradrenaline which acts as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Methyldopa lowers BP by:
A. Inhibiting dopa decarboxylase in adrenergic
nerve endings
B. Generating α-methyl noradrenaline in brain
which reduces sympathetic tone
C. Generating α-methyl noradrenaline which
acts as a false transmitter in peripheral
adrenergic nerve endings
D. Activating vascular dopamine receptors
by

1 Answer

Answer :

B. Generating α-methyl noradrenaline in brain
which reduces sympathetic tone
by

Related questions

Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Description : Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Last Answer : C. Agonistic action on vascular α2 adrenergic receptors

The usual cardiovascular effect of levodopa is: A. Bradycardia due to increased vagal tone B. Rise in blood pressure due to increased noradrenaline content of adrenergic nerve endings C. Fall in blood pressure due to decrease in sympathetic tone D. Both ‘A’ and ‘B’ are correct

Description : The usual cardiovascular effect of levodopa is: A. Bradycardia due to increased vagal tone B. Rise in blood pressure due to increased noradrenaline content of adrenergic nerve endings C. Fall in blood pressure due to decrease in sympathetic tone D. Both ‘A’ and ‘B’ are correct

Last Answer : C. Fall in blood pressure due to decrease in sympathetic tone

The following enzymes on the left are responsible for the synthesis of the neurotransmitters on the right: a. monoamine oxidase: noradrenaline b. cholinesterase: acetylcholine c. catechol-o-methyl transferase: dopamine d. dopa decarboxylase: adrenaline

Description : The following enzymes on the left are responsible for the synthesis of the neurotransmitters on the right: a. monoamine oxidase: noradrenaline b. cholinesterase: acetylcholine c. catechol-o-methyl transferase: dopamine d. dopa decarboxylase: adrenaline

Last Answer : dopa decarboxylase: adrenaline

The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Description : The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Last Answer : A. Tyrosine hydroxylase

The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Description : The rate limiting enzyme in the synthesis of catecholamines is: A. Tyrosine hydroxylase B. Dopa decarboxylase C. Dopamine β-hydroxylase D. Noradrenaline N-methyl transferase

Last Answer : A. Tyrosine hydroxylase

Dantrolene sodium reduces skeletal muscle tone by: A. Reducing acetylcholine release from motor nerve endings B. Suppressing spinal polysynaptic reflexes C. Inhibiting the generation of muscle action potential D. Reducing Ca2+ release from sarcoplasmic reticulum in the muscle fibre

Description : Dantrolene sodium reduces skeletal muscle tone by: A. Reducing acetylcholine release from motor nerve endings B. Suppressing spinal polysynaptic reflexes C. Inhibiting the generation of muscle action potential D. Reducing Ca2+ release from sarcoplasmic reticulum in the muscle fibre

Last Answer : D. Reducing Ca2+ release from sarcoplasmic reticulum in the muscle fibre

All of the following contribute to the antihypertensive action of propranolol except: A. Direct vasodilatation B. Decreased renin release from kidney C. Adaptation of blood vessels to reduced cardiac output D. Less noradrenaline release from sympathetic nerve endings

Description : All of the following contribute to the antihypertensive action of propranolol except: A. Direct vasodilatation B. Decreased renin release from kidney C. Adaptation of blood vessels to reduced cardiac output D. Less noradrenaline release from sympathetic nerve endings

Last Answer : A. Direct vasodilatation

All of the following contribute to the antihypertensive action of propranolol except: A. Direct vasodilatation B. Decreased renin release from kidney C. Adaptation of blood vessels to reduced cardiac output D. Less noradrenaline release from sympathetic nerve endings

Description : All of the following contribute to the antihypertensive action of propranolol except: A. Direct vasodilatation B. Decreased renin release from kidney C. Adaptation of blood vessels to reduced cardiac output D. Less noradrenaline release from sympathetic nerve endings

Last Answer : A. Direct vasodilatation

Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Description : Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Last Answer : C. By a nonexocytotic process

A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is (a) Ephedrine (b) Dopamine (c) Isoprenaline (d) Tyramine

Description : A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is (a) Ephedrine (b) Dopamine (c) Isoprenaline (d) Tyramine

Last Answer : Ans: D

A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Description : A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Last Answer : D. Tyramine

A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Description : A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Last Answer : D. Tyramine

The α 2 adrenoceptors are: A. Located exclusively on the adrenergic nerve endings B. Prejunctional, postjunctional as well as extrajunctional in location C. Selectively activated by phenylephrine D. Selectively blocked by clonidine

Description : The α 2 adrenoceptors are: A. Located exclusively on the adrenergic nerve endings B. Prejunctional, postjunctional as well as extrajunctional in location C. Selectively activated by phenylephrine D. Selectively blocked by clonidine

Last Answer : B. Prejunctional, postjunctional as well as extrajunctional in location

A. It is a clonidine congener used in spasticity due to stroke or spinal injury B. It reduces muscle tone by activating GABAB receptors C. It inhibits release of excitatory amino-acids in spinal interneurones D. It reduces muscle spasms without producing weaknes

Description : A. It is a clonidine congener used in spasticity due to stroke or spinal injury B. It reduces muscle tone by activating GABAB receptors C. It inhibits release of excitatory amino-acids in spinal interneurones D. It reduces muscle spasms without producing weaknes

Last Answer : B. It reduces muscle tone by activating GABAB receptors

In the synthetic pathway of epinephrine, disulfiram (antabuse) inhibits the enzyme: (A) Tyrosine hydroxylase (B) Dopamine β-hydroxylase (C) DOPA decarboxylase (D) N-methyl transferase

Description : In the synthetic pathway of epinephrine, disulfiram (antabuse) inhibits the enzyme: (A) Tyrosine hydroxylase (B) Dopamine β-hydroxylase (C) DOPA decarboxylase (D) N-methyl transferase

Last Answer : Answer : B

The most likely mechanism of antihypertensive action of thiazide diuretics in the long-term is: A. Reduction of circulating blood volume B. Reduction in cardiac output C. Decreased sympathetic tone D. Reduction in total peripheral vascular resistance and improved compliance of resistance vessels

Description : The most likely mechanism of antihypertensive action of thiazide diuretics in the long-term is: A. Reduction of circulating blood volume B. Reduction in cardiac output C. Decreased sympathetic tone D. Reduction in total peripheral vascular resistance and improved compliance of resistance vessels

Last Answer : D. Reduction in total peripheral vascular resistance and improved compliance of resistance vessels

Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Last Answer : C. Do not block any effect of injected adrenaline

Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve stimulation

Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve stimulation

Last Answer : C. Do not block any effect of injected adrenaline

Dobutamine differs from dopamine in that (a) It does not activate peripheral dopaminergic receptors (b) It does not activate adrenergic ß receptors (c) It causes pronounced tachycardia (d) It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that (a) It does not activate peripheral dopaminergic receptors (b) It does not activate adrenergic ß receptors (c) It causes pronounced tachycardia (d) It has good blood-brain barrier penetrability

Last Answer : Ans: A

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Ergotamine relieves migraine by: A. Blocking vascular α adrenergic receptors B. Blocking vascular 5-HT2 receptors C. Dilating cranial arterio-venous shunt channels D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Description : Ergotamine relieves migraine by: A. Blocking vascular α adrenergic receptors B. Blocking vascular 5-HT2 receptors C. Dilating cranial arterio-venous shunt channels D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Last Answer : D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

The following is true of bupropion except: A. It inhibits dopamine reuptake along with inhibiting noradrenaline reuptake B. It produces sedation as a side effect C. It is being used as an aid for smoking cessation D. It is likely to produce seizures in overdose

Description : The following is true of bupropion except: A. It inhibits dopamine reuptake along with inhibiting noradrenaline reuptake B. It produces sedation as a side effect C. It is being used as an aid for smoking cessation D. It is likely to produce seizures in overdose

Last Answer : B. It produces sedation as a side effect

Tyramine induces release of noradrenaline from adrenergic nerve endings (a) By depolarizing the axonal membrane (b) By mobilizing Ca2+ (c) By a nonexocytotic process (d) Only in the presence of MAO inhibitors

Description : Tyramine induces release of noradrenaline from adrenergic nerve endings (a) By depolarizing the axonal membrane (b) By mobilizing Ca2+ (c) By a nonexocytotic process (d) Only in the presence of MAO inhibitors

Last Answer : Ans: C

Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Description : Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Last Answer : C. By a nonexocytotic process

The following is true about entacapone except: A. It acts by inhibiting degradation of dopamine in the brain B. If prolongs the therapeutic effect of levodopacarbidopa in parkinsonism C. It can accentuate levodopa induced dyskinesias D. It can cause diarrhoea as a side effec

Description : The following is true about entacapone except: A. It acts by inhibiting degradation of dopamine in the brain B. If prolongs the therapeutic effect of levodopacarbidopa in parkinsonism C. It can accentuate levodopa induced dyskinesias D. It can cause diarrhoea as a side effec

Last Answer : A. It acts by inhibiting degradation of dopamine in the brain

The antiparkinsonian drug which acts by inhibiting the degradation of dopamine in the brain is: A. Carbidopa B. Amantadine C. Selegiline D. Bromocriptine

Description : The antiparkinsonian drug which acts by inhibiting the degradation of dopamine in the brain is: A. Carbidopa B. Amantadine C. Selegiline D. Bromocriptine

Last Answer : C. Selegiline

The mechanism by which neostigmine improves contraction of myasthenic muscle involves: A. Repetitive binding of the acetylcholine molecules to the same receptors at the muscle endplate B. Diffusion of acetylcholine released from motor nerve endings to a wider area activating neighbouring receptors C. Activation of motor end-plate receptors by neostigmine molecules themselves D. All of the above

Description : The mechanism by which neostigmine improves contraction of myasthenic muscle involves: A. Repetitive binding of the acetylcholine molecules to the same receptors at the muscle endplate B. Diffusion of ... Activation of motor end-plate receptors by neostigmine molecules themselves D. All of the above

Last Answer : D. All of the above

The mechanism by which neostigmine improves contraction of myasthenic muscle involves: A. Repetitive binding of the acetylcholine molecules to the same receptors at the muscle endplate B. Diffusion of acetylcholine released from motor nerve endings to a wider area activating neighbouring receptors C. Activation of motor end-plate receptors by neostigmine molecules themselves D. All of the above

Description : The mechanism by which neostigmine improves contraction of myasthenic muscle involves: A. Repetitive binding of the acetylcholine molecules to the same receptors at the muscle endplate B. Diffusion of ... Activation of motor end-plate receptors by neostigmine molecules themselves D. All of the above

Last Answer : D. All of the above

The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Description : The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Last Answer : A. α-methyl-p-tyrosine

Which of the following statement(s) is/are true concerning the neuroendocrine responses to shock? a. Sympathetic nerve endings release epinephrine which is responsible for greater than 80% of systemic vascular resistance b. Endogenous epinephrine is the primary contributor to systemic vascular resistance c. Increased pancreatic secretion of glucagon contributes to glucose intolerance associated with injury and sepsis d. The renin-angiotensin axis further augments the sympathetic-mediated vasoconstriction

Description : Which of the following statement(s) is/are true concerning the neuroendocrine responses to shock? a. Sympathetic nerve endings release epinephrine which is responsible for greater than 80% ... injury and sepsis d. The renin-angiotensin axis further augments the sympathetic-mediated vasoconstriction

Last Answer : Answer: c, d The neuroendocrine response to shock attempts to achieve restoration of effective blood volume, mobilization of metabolic substrates, and maintenance of central ... . Angiotensin II is an extremely effective vasoconstrictor that further augments sympathetic-mediated vasoconstriction

Adrenaline is inactive orally because it is: A. Not absorbed from the gastrointestinal tract B. Destroyed by gastric acid C. Completely metabolized in the intestinal mucosa and liver before reaching systemic circulation D. Taken up by adrenergic nerve endings of the intestinal wall, liver and lungs

Description : Adrenaline is inactive orally because it is: A. Not absorbed from the gastrointestinal tract B. Destroyed by gastric acid C. Completely metabolized in the intestinal mucosa and liver before reaching systemic circulation D. Taken up by adrenergic nerve endings of the intestinal wall, liver and lungs

Last Answer : C. Completely metabolized in the intestinal mucosa and liver before reaching systemic circulation

The α2 adrenoceptors are: A. Located exclusively on the adrenergic nerve endings B. Prejunctional, postjunctional as well as extrajunctional in location C. Selectively activated by phenylephrine D. Selectively blocked by clonidine

Description : The α2 adrenoceptors are: A. Located exclusively on the adrenergic nerve endings B. Prejunctional, postjunctional as well as extrajunctional in location C. Selectively activated by phenylephrine D. Selectively blocked by clonidine

Last Answer : B. Prejunctional, postjunctional as well as extrajunctional in location

Adrenaline is inactive orally because it is: A. Not absorbed from the gastrointestinal tract B. Destroyed by gastric acid C. Completely metabolized in the intestinal mucosa and liver before reaching systemic circulation D. Taken up by adrenergic nerve endings of the intestinal wall, liver and lungs

Description : Adrenaline is inactive orally because it is: A. Not absorbed from the gastrointestinal tract B. Destroyed by gastric acid C. Completely metabolized in the intestinal mucosa and liver before reaching systemic circulation D. Taken up by adrenergic nerve endings of the intestinal wall, liver and lungs

Last Answer : C. Completely metabolized in the intestinal mucosa and liver before reaching systemic circulation

Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Description : Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Last Answer : C. It does not concurrently enhance noradrenaline release

Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Description : Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Last Answer : A. Adrenaline

Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Description : Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Last Answer : C. It does not concurrently enhance noradrenaline release

Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Description : Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Last Answer : A. Adrenaline

For Catecholamine biosynthesis the rate limiting enzyme is (A) DOPA decarboxylase (B) DOPAMINE β-hydroxylase (C) Tyrosine hydroxylase (D) Phenylalanine hydroxylase

Description : For Catecholamine biosynthesis the rate limiting enzyme is (A) DOPA decarboxylase (B) DOPAMINE β-hydroxylase (C) Tyrosine hydroxylase (D) Phenylalanine hydroxylase

Last Answer : Answer : C

Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Description : The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Last Answer : C. Axonal uptake

6.12 The most prominent action of bromocriptine is: A. Dopamine D2 agonism B. Dopamine D2 antagonism C. Dopamine D1 antagonism D. α adrenergic antagonism

Description : 6.12 The most prominent action of bromocriptine is: A. Dopamine D2 agonism B. Dopamine D2 antagonism C. Dopamine D1 antagonism D. α adrenergic antagonism

Last Answer : A. Dopamine D2 agonism

Initial bradycardia caused by intramuscular injection of atropine is believed to be caused by: A. Stimulation of medullary vagal centre B. Stimulation of vagal ganglia C. Blockade of M2 receptors on SA nodal cells D. Blockade of muscarinic autoreceptors on vagal nerve endings

Description : Initial bradycardia caused by intramuscular injection of atropine is believed to be caused by: A. Stimulation of medullary vagal centre B. Stimulation of vagal ganglia C. Blockade of M2 receptors on SA nodal cells D. Blockade of muscarinic autoreceptors on vagal nerve endings

Last Answer : D. Blockade of muscarinic autoreceptors on vagal nerve endings

Initial bradycardia caused by intramuscular injection of atropine is believed to be caused by: A. Stimulation of medullary vagal centre B. Stimulation of vagal ganglia C. Blockade of M2 receptors on SA nodal cells D. Blockade of muscarinic autoreceptors on vagal nerve endings

Description : Initial bradycardia caused by intramuscular injection of atropine is believed to be caused by: A. Stimulation of medullary vagal centre B. Stimulation of vagal ganglia C. Blockade of M2 receptors on SA nodal cells D. Blockade of muscarinic autoreceptors on vagal nerve endings

Last Answer : D. Blockade of muscarinic autoreceptors on vagal nerve endings

Adrenaline raises blood glucose level by the following actions except: A. Inducing hepatic glycogenolysis B. Inhibiting insulin secretion from pancreatic β cells C. Augmenting glucagon secretion from pancreatic α cells D. Inhibiting peripheral glucose utilization

Description : Adrenaline raises blood glucose level by the following actions except: A. Inducing hepatic glycogenolysis B. Inhibiting insulin secretion from pancreatic β cells C. Augmenting glucagon secretion from pancreatic α cells D. Inhibiting peripheral glucose utilization

Last Answer : D. Inhibiting peripheral glucose utilization

Adrenaline raises blood glucose level by the following actions except: A. Inducing hepatic glycogenolysis B. Inhibiting insulin secretion from pancreatic β cells C. Augmenting glucagon secretion from pancreatic α cells D. Inhibiting peripheral glucose utilization

Description : Adrenaline raises blood glucose level by the following actions except: A. Inducing hepatic glycogenolysis B. Inhibiting insulin secretion from pancreatic β cells C. Augmenting glucagon secretion from pancreatic α cells D. Inhibiting peripheral glucose utilization

Last Answer : D. Inhibiting peripheral glucose utilization

Injection of adrenaline along with a local anaesthetic serves the following purpose: A. Lowers the concentration of the local anaesthetic to produce nerve block B. Prolongs the duration of local anaesthesia C. Increases the anaesthetised area D. Reduces the local toxicity of the local anaesthetic

Description : Injection of adrenaline along with a local anaesthetic serves the following purpose: A. Lowers the concentration of the local anaesthetic to produce nerve block B. Prolongs the duration of local anaesthesia C. Increases the anaesthetised area D. Reduces the local toxicity of the local anaesthetic

Last Answer : B. Prolongs the duration of local anaesthesia

The rate limiting step in catecholamine synthesis is catalysed by (A) Phenylalanine hydroxylase (B) Tyrosine hydroxylase (C) Dopa decarboxylase (D) Phenylethanolamine N-methyl transferase

Description : The rate limiting step in catecholamine synthesis is catalysed by (A) Phenylalanine hydroxylase (B) Tyrosine hydroxylase (C) Dopa decarboxylase (D) Phenylethanolamine N-methyl transferase

Last Answer : Answer : B